Rheumatoid Arthritis | Chart Trends | US | 2014
The Rheumatoid Arthritis (RA) treatment paradigm continues to evolve as new therapeutic options are added to physicians’ toolkits. The positioning of newer agents (e.g., Pfizer’s Xeljanz, Janssen’s Simponi Aria) in the treatment algorithm is still being established in some cases, and has reached a relative steady state in others. ChartTrends®: Rheumatoid Arthritis (US) 2014 explores the current status quo in RA treatment based on both physician reports and actual practice through the use of patient chart data.
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
